	US 11,806,400 B2
	Injectable ibuprofen formulation
Leo Pavliv, Cary, NC (US); and Andrew Vila, Nashville, TN (US)
Assigned to Cumberland Pharmaceuticals Inc., Nashville, TN (US)
Filed by Cumberland Pharmaceuticals Inc., Nashville, TN (US)
Filed on May 7, 2020, as Appl. No. 16/869,277.
Application 16/869,277 is a continuation of application No. 16/249,884, filed on Jan. 16, 2019, abandoned.
Application 16/249,884 is a continuation of application No. 14/755,297, filed on Jun. 30, 2015, abandoned.
Application 14/755,297 is a continuation of application No. 13/422,761, filed on Mar. 16, 2012, granted, now 9,072,710, issued on Jul. 7, 2015.
Prior Publication US 2020/0261581 A1, Aug. 20, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/02 (2006.01); A61J 1/06 (2006.01); A61J 1/10 (2006.01); A61K 31/192 (2006.01); A61P 29/00 (2006.01)

CPC A61K 47/02 (2013.01) [A61J 1/065 (2013.01); A61J 1/10 (2013.01); A61K 31/192 (2013.01); A61P 29/00 (2018.01)]

16 Claims

1. A pre-filled bag for intravenous injection containing a stable pharmaceutical composition comprising water for injection, 4 mg/mL ibuprofen, sodium chloride, and sodium hydroxide, wherein the sodium hydroxide to ibuprofen molar ratio is at least 1.05:1, and wherein the pharmaceutical composition is clear and has a pH of 7.4.